Table 1 Evolution of consumption in DID of the different families of anti-asthmatic generic drugs in Morocco
From: Factors influencing anti-asthmatic generic drug consumption in Morocco: 1999-2010
Class | 1999 | 2010 | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Total Antiasthmatics | Antiasthmatics GD | Total Antiasthmatics | Antiasthmatics GD | |||||||||
NS | NP | DID | NS | NP | DID (%) | NS | NP | DID | NS | NP | DID (%) | |
SABA | 7 | 9 | 1.95 | 2 | 2 | 0.4 (21.86%) | 8 | 12 | 3.99 | 6 | 8 | 0.73 (33.48%) |
LABA | 2 | 3 | 0.03 | —— | —— | —— | 2 | 2 | 0.04 | 1 | 1 | 0.0006 (0.03%) |
Systemic beta2- agonists | 4 | 14 | 0.27 | 3 | 7 | 0.15 (8.19%) | 6 | 13 | 0.35 | 5 | 10 | 0.26 (11.92%) |
IC | 5 | 9 | 0.71 | 3 | 4 | 0.65 (35.52%) | 9 | 13 | 1.13 | 7 | 8 | 0.83 (38.07%) |
LABA-IC | —— | —— | —— | —— | —— | —— | 4 | 12 | 3.58 | 2 | 6 | 0.18 (8.25%) |
Injectable Xanthines | 9 | 22 | 0.95 | 7 | 18 | 0.63 (34.43%) | 5 | 12 | 0.38 | 3 | 9 | 0.18 (8.25%) |
Total | 27 | 57 | 3 .91 | 15 | 31 | 1.83 (100%) | 34 | 64 | 9.47 | 24 | 42 | 2.18 (100%) |